Jun. 26 at 4:16 PM
@APLD : yes. The institutions & investment banks are likely the ones buying the dip - it took me one look at the slides to realize this was skewed due to historical outperformance in the placebo arm causing them to miss stat sig on one EP. The stock sold off this morning as if the trial had failed.
$ALT is already rebounding - it will likely stay in the
$3S for today.
So the “tutes” and other smart retail are likely buying and will reiterate their outperform targets because the phase 3 design is what matters most now (and how they fund it - hopefully they’ll avoid dilution and look at a
$RVMD or other type of novel deal)
Their results look great as noted by the KOL on the call.
Of the slides they presented this morning: this is the key one. Look at the 25% on placebo who responded- like the 7% from 89 bio these are clearly outliers (good for them, bully for AltImmune).
